Table 2

 Change from baseline in Health Assessment Questionnaire and Short Form-36 scores

Week 14Week 24
PlaceboInfliximabp ValuePlaceboInfliximabp Value
*Data are expressed as means, and p values were based on a non-parametric analysis.
HAQ, Health Assessment Questionnaire; SF-36, Short Form-36; PCS, physical component summary; MCS, mental component summary; PF, physical functioning; RP, role-physical; BP, bodily pain; GH, general health; VT, vitality; SF, social functioning; RE, role-emotional; MH, mental health.
HAQ
Percentage improvement*−18.448.6<0.001−19.446.0<0.001
Percentage of patients with at least a 0.3 decrease19.458.6<0.00120.052.1<0.001
SF-36*
PCS1.19.1<0.0011.37.7<0.001
MCS−1.23.80.0010.43.90.047
PF−0.217.7<0.0011.315.3<0.001
RP5.230.1<0.0019.425.50.010
BP3.222.9<0.0014.021.6<0.001
GH−2.611.9<0.001−1.89.4<0.001
VT1.912.7<0.0011.512.8<0.001
SF−0.513.4<0.0012.612.90.007
RE−4.916.80.0021.413.30.093
MH−1.69.1<0.0011.39.40.002